Equitable Trust Co. Sells 444 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Equitable Trust Co. decreased its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 16.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,313 shares of the company’s stock after selling 444 shares during the period. Equitable Trust Co.’s holdings in Medpace were worth $768,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. R Squared Ltd bought a new stake in Medpace during the fourth quarter valued at $30,000. Stone House Investment Management LLC bought a new stake in Medpace during the third quarter worth about $33,000. Ashton Thomas Securities LLC bought a new stake in Medpace during the third quarter worth about $37,000. Capital Performance Advisors LLP bought a new stake in Medpace during the third quarter worth about $46,000. Finally, True Wealth Design LLC lifted its stake in Medpace by 16,800.0% during the third quarter. True Wealth Design LLC now owns 169 shares of the company’s stock worth $56,000 after purchasing an additional 168 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on MEDP. Robert W. Baird lifted their price target on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. TD Cowen dropped their price target on Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Redburn Atlantic began coverage on Medpace in a research note on Monday, October 14th. They set a “buy” rating and a $404.00 price target for the company. Baird R W lowered Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Finally, Truist Financial lowered their target price on Medpace from $415.00 to $397.00 and set a “hold” rating for the company in a research note on Monday, October 14th. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $381.44.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $354.51 on Tuesday. Medpace Holdings, Inc. has a 1 year low of $302.01 and a 1 year high of $459.77. The company has a market cap of $11.02 billion, a PE ratio of 31.04, a P/E/G ratio of 1.85 and a beta of 1.36. The stock’s 50-day moving average is $343.88 and its 200 day moving average is $349.52.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 50.87% and a net margin of 17.66%. Analysts expect that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.